Eli Lilly and Co

Eli Lilly's QWINT clinical trials show once-weekly insulin efsitora alfa non-inferior A1C reduction in type 2 diabetes compared to daily basal insulins. QWINT-1 and QWINT-3 met primary endpoints of non-inferior A1C reduction at weeks 52 and 26, respectively. Efsitora aims to simplify insulin therapy, potentially transforming diabetes care.

Eli Lilly's weekly insulin injection, efsitora alfa, showed superior A1C reduction in Phase III trials, potentially challenging Novo Nordisk. Weekly injections demonstrated similar safety and efficacy to daily insulin, enhancing patient convenience and compliance.

Patients struggle to get obesity and diabetes drugs like Wegovy and Mounjaro due to high demand and supply shortages. Drugmakers Novo Nordisk and Eli Lilly report availability but patients still face difficulties. The FDA monitors the situation, and drug companies are expanding production. Signs of easing shortages include the return of pharmaceutical samples to doctors' offices.

TD Cowen maintains Buy rating and $1,050.00 price target for Eli Lilly, following successful Phase III trial results for once-weekly insulin efsitora. Analysts predict potential market impact, with efsitora seen as a competitor to Novo Nordisk's icodec. Eli Lilly's financial model has been revised, reflecting heightened expectations. Recent collaborations and acquisitions, including a deal with EVA Pharma and the acquisition of Morphic Holding, add to the company's growth prospects. Eli Lilly's market capitalization stands at $831.03 billion, with impressive revenue growth and consistent dividend payments.

M.J.D. has consulted, advised, and spoken for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, AstraZeneca, Zealand Pharma, Carmot/Roche, and Amgen. She has also received grants from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janssen, Sanofi-Aventis, and Eli Lilly. J.G. has no competing interests.

Eli Lilly's once-weekly insulin efsitora alfa (efsitora) showed similar HbA1C reduction to daily injections in type 2 diabetes patients, potentially simplifying insulin therapy and improving quality of life.

Eli Lilly's Phase III trials of once-weekly insulin efsitora alfa (efsitora) for type 2 diabetes showed non-inferior A1C reduction compared to insulin glargine and similar reduction to insulin degludec. Efsitora's safety and tolerability profile aligns with daily basal insulin therapies, suggesting it could be an effective once-weekly basal insulin therapy.

Most large employers plan to cover GLP-1 drugs for obesity in 2025, despite cost concerns. Employers anticipate increased spending on GLP-1 drugs, with 40% planning to cover them for cardiovascular conditions in 2025. Employers use prior authorization and weight management programs to manage costs.

Eli Lilly launched a new version of Zepbound in single-dose vials to address supply issues, priced at $399 and $549 for four-week supplies. This move aims to boost revenue in the expanding weight loss drug market, which could reach $100 billion by the end of the decade.